Literature DB >> 15627176

Safety of MR liver specific contrast media.

Marie-France Bellin1, Judith A W Webb, Aart J Van Der Molen, Henrik S Thomsen, Sameh K Morcos.   

Abstract

Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627176     DOI: 10.1007/s00330-004-2612-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  47 in total

1.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.

Authors:  J Petersein; A Spinazzi; A Giovagnoni; P Soyer; F Terrier; R Lencioni; C Bartolozzi; L Grazioli; A Chiesa; R Manfredi; P Marano; E L Van Persijn Van Meerten; J L Bloem; C Petre; G Marchal; A Greco; M T McNamara; A Heuck; M Reiser; M Laniado; C Claussen; H E Daldrup; E Rummeny; M A Kirchin; G Pirovano; B Hamm
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

Review 2.  Contrast agents for magnetic resonance imaging: safety update.

Authors:  Miles A Kirchin; Val M Runge
Journal:  Top Magn Reson Imaging       Date:  2003-10

3.  Interim results of phase II clinical testing of gadobenate dimeglumine.

Authors:  G Rosati; G Pirovano; A Spinazzi
Journal:  Invest Radiol       Date:  1994-06       Impact factor: 6.016

4.  Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging.

Authors:  M Federle; J Chezmar; D L Rubin; J Weinreb; P Freeny; U P Schmiedl; J J Brown; J A Borrello; J K Lee; R C Semelka; R Mattrey; A H Dachman; S Saini; S E Harms; D G Mitchell; M W Anderson; H H Halford; W F Bennett; S W Young; M Rifkin; S B Gay; R Ballerini; P F Sherwin; R O Robison
Journal:  J Magn Reson Imaging       Date:  2000-11       Impact factor: 4.813

5.  Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.

Authors:  W W Mayo-Smith; W Schima; S Saini; G J Slater; E G McFarland
Journal:  AJR Am J Roentgenol       Date:  1998-03       Impact factor: 3.959

Review 6.  Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA.

Authors:  B Hamm; M Kirchin; G Pirovano; A Spinazzi
Journal:  J Comput Assist Tomogr       Date:  1999-11       Impact factor: 1.826

7.  Dynamic MR imaging of liver metastases with Gd-EOB-DTPA.

Authors:  W Stern; F Schick; A F Kopp; P Reimer; K Shamsi; C D Claussen; M Laniado
Journal:  Acta Radiol       Date:  2000-05       Impact factor: 1.990

Review 8.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

9.  MnDPDP for MR imaging of the liver. Results from the European phase III studies.

Authors:  C G Torres; B Lundby; A T Sterud; S McGill; P B Gordon; H S Bjerknes
Journal:  Acta Radiol       Date:  1997-07       Impact factor: 1.701

10.  Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration.

Authors:  S O Hustvedt; D Grant; T E Southon; K Zech
Journal:  Acta Radiol       Date:  1997-07       Impact factor: 1.701

View more
  9 in total

1.  Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers.

Authors:  Nils Albiin; Nikolaos Kartalis; Annika Bergquist; Bita Sadigh; Torkel B Brismar
Journal:  MAGMA       Date:  2012-03-08       Impact factor: 2.310

2.  The T2-shortening effect of gadolinium and the optimal conditions for maximizing the CNR for evaluating the biliary system: a phantom study.

Authors:  Mi-Jung Lee; Myung-Joon Kim; Choon-Sik Yoon; Si Young Song; Kyungsoo Park; Woo Sun Kim
Journal:  Korean J Radiol       Date:  2011-04-26       Impact factor: 3.500

3.  Spontaneous Biliary Perforations: An Uncommon yet Important Entity in Children.

Authors:  Prabudh Goel; Vishesh Jain; Vivek Manchanda; Mamta Sengar; Chhabi Ranu Gupta; Anup Mohta
Journal:  J Clin Diagn Res       Date:  2013-06-01

4.  MR cholangiopancreatography findings in children with spontaneous bile duct perforation.

Authors:  Mi-Jung Lee; Myung-Joon Kim; Choon-Sik Yoon
Journal:  Pediatr Radiol       Date:  2010-01-15

5.  Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

Authors:  Guenther Schneider; Hellmut Schürholz; Miles A Kirchin; Arno Bücker; Peter Fries
Journal:  Pediatr Radiol       Date:  2012-11-24

6.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

Review 7.  The role of gadoxetic acid as a paramagnetic contrast medium in the characterization and detection of focal liver lesions: a review.

Authors:  Renata Lilian Bormann; Eduardo Lima da Rocha; Marcelo Longo Kierzenbaum; Bruno Cheregati Pedrassa; Lucas Rios Torres; Giuseppe D'Ippolito
Journal:  Radiol Bras       Date:  2015 Jan-Feb

8.  Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.

Authors:  Kim-Lien Nguyen; Takegawa Yoshida; Nikhita Kathuria-Prakash; Islam H Zaki; Csanad G Varallyay; Scott I Semple; Rola Saouaf; Cynthia K Rigsby; Sokratis Stoumpos; Kevin K Whitehead; Lindsay M Griffin; David Saloner; Michael D Hope; Martin R Prince; Mark A Fogel; Mark L Schiebler; Giles H Roditi; Aleksandra Radjenovic; David E Newby; Edward A Neuwelt; Mustafa R Bashir; Peng Hu; J Paul Finn
Journal:  Radiology       Date:  2019-10-22       Impact factor: 11.105

Review 9.  Description of focal liver lesions with Gd-EOB-DTPA enhanced MRI.

Authors:  Cosmin-Nicolae Caraiani; Marian Dan; Diana-Ioana Fenesan; Radu Badea
Journal:  Clujul Med       Date:  2015-11-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.